Breaking News Instant updates and real-time market news.

AAPL

Apple

$188.55

-2.56 (-1.34%)

, GS

Goldman Sachs

$188.87

0.3 (0.16%)

13:43
03/25/19
03/25
13:43
03/25/19
13:43

Apple partners with Goldman Sachs, Mastercard to launch Apple Card

Apple (AAPL) announced Apple Card, which the company describes as "an innovative, new kind of credit card created by Apple and designed to help customers lead a healthier financial life. Apple Card is built into the Apple Wallet app on iPhone, offering customers a familiar experience with Apple Pay and the ability to manage their card right on iPhone. Apple Card transforms the entire credit card experience by simplifying the application process, eliminating fees, encouraging customers to pay less interest and providing a new level of privacy and security. Available in the US this summer, Apple Card also offers a clearer and more compelling rewards program than other credit cards with Daily Cash, which gives back a percentage of every purchase as cash on customers' Apple Cash card each day." Customers will receive 2% Daily Cash for every use of the card and will get 3% Daily Cash on all purchases made directly with Apple, including at Apple Stores, on the App Store and for Apple services, the company said. Apple is partnering with Goldman Sachs (GS) and Mastercard (MA) to provide the support of an issuing bank and global payments network. "As a newcomer to consumer financial services, Goldman Sachs is creating a different credit card experience centered around the customer, which includes never sharing or selling data to third parties for marketing and advertising. Mastercard will provide cardholders the ability to shop at merchants around the globe," Apple said. Apple Card will be available to qualified customers in the U.S. this summer.

AAPL

Apple

$188.55

-2.56 (-1.34%)

GS

Goldman Sachs

$188.87

0.3 (0.16%)

MA

MasterCard

$229.47

-1.3 (-0.56%)

  • 25

    Mar

  • 15

    Apr

  • 03

    Jun

  • 25

    Jun

AAPL Apple
$188.55

-2.56 (-1.34%)

03/22/19
JPMS
03/22/19
UPGRADE
Target $65
JPMS
Overweight
JPMorgan upgrades Lumentum to Overweight on iPhone volume stabilization
JPMorgan analyst Samik Chatterjee upgraded Lumentum Holdings (LITE) to Overweight from Neutral and raised his price target for the shares to $65 from $50. The stock closed yesterday up $2.44, of 5%, to $52.10. The analyst sees a "solid" outlook for the company's telecom business amid "strong" growth led by 5G investments and upside to synergy targets relative to recent acquisition of Oclaro. Further, he sees limited downside risk relative to volume expectations for Apple's (AAPL) iPhone, which he notes has been a "key driver of sentiment on the shares." Stabilization of its iPhone volume outlook should drive focus back to the "strong" fundamentals in Lumentum's primary telecom business, Chatterjee tells investors in a research note.
03/22/19
MSCO
03/22/19
NO CHANGE
MSCO
Overweight
Apple streaming service timing, robustness key details, says Morgan Stanley
Morgan Stanley analyst Katy Huberty said she expects next Monday's special event from Apple to be focused on new Services launches, specifically a streaming video on demand service and likely a paid subscription news and magazine service. Huberty believes that besides the launch of an Apple Media bundle, which she would view as the most bullish potential announcement, the inclusion of video content from other programmers would be a positive and the launch timing and robustness of the offerings are the most important details to watch. A meaningful delay in the launch of original video content could hamper customer adoption and pricing at or above market for a stand-alone streaming video service could also slow adoption, said Huberty, who has an Overweight rating on Apple shares.
03/25/19
BTIG
03/25/19
NO CHANGE
Target $220
BTIG
Buy
Apple price target raised to $220 from $189 at BTIG
BTIG analyst Walter Piecyk raised his price target on Apple to $220 and kept his Buy rating ahead of its product event today, saying that while the rally of the stock price could stall, his new target assumes the company will return to growth in 2020. The analyst notes that while the recent data points have not been positive for Apple's iPhone business expectations, he continues to expect abating lengthening of the product cycle to materialize in 2020. Piecyk adds that stock buybacks and the company's capital program should be the primary driver Apple's earnings growth.
03/21/19
RHCO
03/21/19
NO CHANGE
RHCO
Apple event may be negative for Netflix, positive for Lions Gate, says SunTrust
SunTrust analyst Matthew Thornton previews Apple's (AAPL) media event scheduled for March 25th, saying the company is likely to unveil a Video Service. The analyst believes that an Apple OTT service could be a positive for Lions Gate (LGF.B) given the participation of the Starz networks but negative for Netflix (NFLX) "if Apple can offer compelling content bundles at compelling prices with a compelling UI and ubiquitous access". Thornton adds that Apple's bundling of its Music with video subscriptions and news subscriptions may be a negative for Spotify (SPOT) and a "modest incremental negative" for Roku (ROKU) if Apple's service app is not on its service.
GS Goldman Sachs
$188.87

0.3 (0.16%)

02/01/19
02/01/19
DOWNGRADE

Sell
Societe Generale downgrades Goldman Sachs, Morgan Stanley to Sell
As previously reported, Societe Generale analyst Andrew Lim downgraded Goldman Sachs (GS) and Morgan Stanley (MS), both to Sell from Hold, citing his view that the credit cycle deterioration "has already been set in motion" and that it will pay to be defensive for the rest of 2019. Goldman and Morgan are much more exposed to pressure on market-sensitive revenues as purer investment banks, Lim tells investors. He does not have any Buy ratings on big U.S. banks, but continues to favor holding positions in Bank of America (BAC) and JP Morgan (JPM), which Lim views as the most defensive large cap U.S. banks, he tells investors.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
03/01/19
SBSH
03/01/19
NO CHANGE
SBSH
Neutral
Goldman Sachs faces 'tough legal setup' in 1MDB case, says Citi
Goldman Sachs' alleged role in the ongoing 1MDB scandal has weighed on the stock since November, Citi analyst Keith Horowitz tells investors in a research note. After researching the case and speaking with a subject matter expert, the analyst thinks Goldman "faces a tough legal setup" in the 1MDB case. He expects the company to settle with regulators and estimates a range of penalties from $1.5B to $9.0B, with a base case of $4B-$5B. He sees suspended business activities as unlikely. Despite the 14% underperformance since November, Goldman shares are fairly valued given continued 1MDB overhang, Horowitz tells investors in a research note. He keeps a Neutral rating on the shares.
02/21/19
02/21/19
INITIATION

Odeon's Dick Bove starts Goldman Sachs with Sell rating
Odeon analyst Dick Bove initiated coverage of Goldman Sachs with a Sell rating. Now is not the time to own the stock as indications are growing that Goldman's legal issues "are just beginning related to the events in Malaysia," Bove tells investors in a research note. The analyst adds that the Federal Reserve and U.S. Justice Department are also investigating these events and that fines are expected. Goldman Sachs in late morning trading is down $2.00 to $196.60.
MA MasterCard
$229.47

-1.3 (-0.56%)

02/19/19
BTIG
02/19/19
NO CHANGE
Target $114
BTIG
Buy
PayPal price target raised to $114 from $95 at BTIG
BTIG analyst Mark Palmer raised his price target on PayPal (PYPL) to $114 and kept his Buy rating, citing the company's "multi-faceted" growth story that includes accelerating active account additions, continued increases in customer engagement, and acceleration of Venmo payment volume. The analyst believes that PayPal can drive growth rates that are "about twice that of its peer group", justifying the premium of the stock relative to its peers. Palmer adds that PayPal shares still trade at a discount relative to MasterCard (MA) based on its enterprise value to expected FY21 EBITDA multiple.
02/20/19
NOMU
02/20/19
NO CHANGE
Target $252
NOMU
Buy
MasterCard price target raised to $252 from $226 at Nomura Instinet
Nomura Instinet analyst Bill Carcache raised his price target for MasterCard to $252 after meeting with management and keeps a Buy rating on the shares.
03/25/19
JEFF
03/25/19
NO CHANGE
Target $175
JEFF
Buy
Visa price target raised to $175 from $170 at Jefferies
Jefferies analyst Michael Del Grosso raised his price target for Visa (V) to $175 from $170 after hosting investor meetings at the company's headquarters. Visa's "innovative capabilities" are underappreciated relative to MasterCard (MA) and its upcoming product roll-outs "may help close this perception gap," Del Grosso tells investors in a research note. He believes Visa's core growth story is intact and that new product capabilities "enhance the volume opportunity for the foreseeable future." The analyst reiterates a Buy rating on the shares.
03/14/19
WEDB
03/14/19
NO CHANGE
Target $235
WEDB
Outperform
MasterCard price target raised to $235 from $220 at Wedbush
Wedbush analyst Moshe Katri raised his price target for MasterCard to $235 from $220 as he likes the company's attractive business model, growth prospects and outlook for increasing shareholder returns. From a "big-picture" perspective, the analyst points to a host of growth/scale catalysts, including the disintermediation of cash/checks by electronic payments, networks' increased dominance in the payments' ecosystem, incremental revenue opportunities from European regulations, incremental catalysts from hyper-growth mobile payments, ACH-based revenue growth opportunities, increased traction in B2B, and potential revenue synergies from MasterCard's consulting practice. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

07:56
12/07/19
12/07
07:56
12/07/19
07:56
Hot Stocks
AbbVie announces data from Phase 2 lymphocytic leukemia study »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:51
12/07/19
12/07
07:51
12/07/19
07:51
Hot Stocks
Janssen announces initial results from Phase 1b/2 multiple myeloma study »

Janssen Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

XBIT

XBiotech

$11.11

0.1 (0.91%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:46
12/07/19
12/07
07:46
12/07/19
07:46
Hot Stocks
XBiotech sells bermekimab to Janssen for $750M plus potential milestones »

XBiotech (XBIT) announced…

XBIT

XBiotech

$11.11

0.1 (0.91%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:39
12/07/19
12/07
07:39
12/07/19
07:39
Hot Stocks
PG&E to amend and finalize bankruptcy plan following settlement »

PG&E said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.